• Something wrong with this record ?

Consensus statement on enzyme replacement therapy for mucopolysaccharidosis IVA in Central and South-Eastern European countries

M. Magner, Z. Almássy, Z. Gucev, B. Kieć-Wilk, V. Plaiasu, A. Tylki-Szymańska, D. Zafeiriou, I. Zaganas, C. Lampe

. 2022 ; 17 (1) : 190. [pub] 20220510

Language English Country Great Britain

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc22018437

BACKGROUND: Mucopolysaccharidosis IVA (MPS IVA), or Morquio A syndrome, is a rare inherited metabolic disorder caused by deficiency of the lysosomal enzyme N-acetylgalactosamine-6-sulfatase. A progressive systemic skeletal chondrodysplasia, leading to significant morbidity and reduced life expectancy is the main clinical feature of this multisystemic disease. Although enzyme replacement therapy with elosulfase alfa is established in Europe, the rarity of disease and other factors still set hurdles in having patients treated in some countries. Aim of this statement is to provide evidence-based guidance for the enzyme replacement treatment of Morquio A patients, harmonizing recommendations from published guidelines with the real-life clinical practice in the Central and South-Eastern European region. PARTICIPANTS: The Consensus Group, convened by 8 Steering Committee (SC) members from 7 Central and South-Eastern European countries, consisted of a multidisciplinary group of 17 experts in the management of MPS in Central and South-Eastern Europe. CONSENSUS PROCESS: The SC met in a first virtual meeting with an external scientific coordinator, to discuss on clinical issues to be analyzed in guidance statements. Statements were developed by the scientific coordinator, evaluated by the SC members in a first modified-Delphi voting and adapted accordingly, to be submitted to the widest audience in the Consensus Conference. Following discussion and further modifications, all participants contributed to a second round of modified-Delphi voting. RESULTS: Nine of ten statements, concerning general guidelines for management of MPS IVA patients and specific recommendations for treatment, received final consensus. CONCLUSIONS: European guidelines and evidence-based recommendations for Morquio A patients should be considered in the real life of Central and South-Eastern European countries and adapted to unique clinical practice approaches and criteria for patients' access to treatment and reimbursement in the region.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22018437
003      
CZ-PrNML
005      
20220804134753.0
007      
ta
008      
220720s2022 xxk f 000 0|eng||
009      
AR
024    7_
$a 10.1186/s13023-022-02332-7 $2 doi
035    __
$a (PubMed)35538504
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxk
100    1_
$a Magner, Martin $u Department of Paediatrics and Inherited Metabolic Disorders, General University Hospital and First Faculty of Medicine, Charles University, KPDPM 1. LF UK a VFN v Praze, Ke Karlovu 2, 128 08, Prague, Czech Republic. martin.magner@vfn.cz $1 https://orcid.org/0000000258839509
245    10
$a Consensus statement on enzyme replacement therapy for mucopolysaccharidosis IVA in Central and South-Eastern European countries / $c M. Magner, Z. Almássy, Z. Gucev, B. Kieć-Wilk, V. Plaiasu, A. Tylki-Szymańska, D. Zafeiriou, I. Zaganas, C. Lampe
520    9_
$a BACKGROUND: Mucopolysaccharidosis IVA (MPS IVA), or Morquio A syndrome, is a rare inherited metabolic disorder caused by deficiency of the lysosomal enzyme N-acetylgalactosamine-6-sulfatase. A progressive systemic skeletal chondrodysplasia, leading to significant morbidity and reduced life expectancy is the main clinical feature of this multisystemic disease. Although enzyme replacement therapy with elosulfase alfa is established in Europe, the rarity of disease and other factors still set hurdles in having patients treated in some countries. Aim of this statement is to provide evidence-based guidance for the enzyme replacement treatment of Morquio A patients, harmonizing recommendations from published guidelines with the real-life clinical practice in the Central and South-Eastern European region. PARTICIPANTS: The Consensus Group, convened by 8 Steering Committee (SC) members from 7 Central and South-Eastern European countries, consisted of a multidisciplinary group of 17 experts in the management of MPS in Central and South-Eastern Europe. CONSENSUS PROCESS: The SC met in a first virtual meeting with an external scientific coordinator, to discuss on clinical issues to be analyzed in guidance statements. Statements were developed by the scientific coordinator, evaluated by the SC members in a first modified-Delphi voting and adapted accordingly, to be submitted to the widest audience in the Consensus Conference. Following discussion and further modifications, all participants contributed to a second round of modified-Delphi voting. RESULTS: Nine of ten statements, concerning general guidelines for management of MPS IVA patients and specific recommendations for treatment, received final consensus. CONCLUSIONS: European guidelines and evidence-based recommendations for Morquio A patients should be considered in the real life of Central and South-Eastern European countries and adapted to unique clinical practice approaches and criteria for patients' access to treatment and reimbursement in the region.
650    _2
$a vrozené poruchy metabolismu aminokyselin $7 D000592
650    _2
$a konsensus $7 D032921
650    _2
$a enzymová substituční terapie $7 D056947
650    _2
$a lidé $7 D006801
650    _2
$a isovaleryl-CoA-dehydrogenasa $x nedostatek $7 D050769
650    12
$a mukopolysacharidózy $x farmakoterapie $7 D009083
650    12
$a mukopolysacharidóza IV $x farmakoterapie $7 D009085
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Almássy, Zsuzsanna $u Department of Toxicology and Metabolic Diseases, Heim Pal National Pediatric Institute, Budapest, Hungary
700    1_
$a Gucev, Zoran $u University Children's Hospital, Skopje, North Macedonia
700    1_
$a Kieć-Wilk, Beata $u Unit of Rare Metabolic Diseases, Department of Metabolic Diseases, Jagiellonian University Medical College, University Hospital, Krakow, Poland
700    1_
$a Plaiasu, Vasilica $u Regional Centre of Medical Genetics, INSMC Alessandrescu-Rusescu, Bucharest, Romania
700    1_
$a Tylki-Szymańska, Anna $u Department of Pediatric Nutrition and Metabolic Diseases, The Children's Memorial Health Institute, Warsaw, Poland
700    1_
$a Zafeiriou, Dimitrios $u First Department of Pediatrics, Hippokratio General Hospital, Aristotle University, Thessaloniki, Greece
700    1_
$a Zaganas, Ioannis $u Neurogenetics Laboratory, Neurology Department, University Hospital of Heraklion, University of Crete, Heraklion, Greece
700    1_
$a Lampe, Christina $u Department of Child Neurology, Epileptology and Social Pediatrics, Centre for Rare Diseases, University of Giessen, Giessen, Germany
773    0_
$w MED00165365 $t Orphanet journal of rare diseases $x 1750-1172 $g Roč. 17, č. 1 (2022), s. 190
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35538504 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804134747 $b ABA008
999    __
$a ok $b bmc $g 1822159 $s 1169680
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 17 $c 1 $d 190 $e 20220510 $i 1750-1172 $m Orphanet journal of rare diseases $n Orphanet J Rare Dis $x MED00165365
LZP    __
$a Pubmed-20220720

Find record

Citation metrics

Archiving options